Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2024-09-13 Declaration of Voting R…
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the First Extraordinary General Meeting (EGM) of Pharmaron Beijing Co., Ltd. It details the voting outcomes on resolutions proposed at the EGM, including engagement of auditors for 2024. The text includes voting percentages, number of shares voted, and confirms the resolutions were passed. There is no detailed financial data, management discussion, or full report content. The document is a formal announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4682 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2024-09-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, share options, warrants, convertibles, other agreements to issue shares, and repurchase of shares. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and shareholding changes for the month. It is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory filing reporting share capital movements and share repurchase details as required by exchange rules. The document length (8809 characters) and content indicate it is a substantive regulatory filing rather than a brief announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-09-04 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2024-08-27 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024' and contains detailed financial statements including condensed consolidated statements of profit or loss, comprehensive income, financial position, and notes to the interim condensed consolidated financial statements. It covers a six-month period ending June 30, 2024, which is a period shorter than a full fiscal year. The document includes substantive financial data and analysis, not just a brief announcement or summary. The presence of detailed financial statements and notes prepared under IAS 34 Interim Financial Reporting confirms this is an Interim / Quarterly Report. It is not a full annual report (10-K), nor a simple earnings release or announcement. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2024
2024-08-27 English
Notification Letter and Request Form to Non-registered Shareholders - Notification of publication of Circular and Notice of the First Extraordinary General Meeting of 2024
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 27 August 2024 from Pharmaron Beijing Co., Ltd. informing non-registered shareholders about the publication of the Circular and Notice for the First Extraordinary General Meeting of 2024 on the company's and HKEX's websites. It includes instructions on how to request printed copies of these corporate communications. The document does not contain the actual Circular or Notice but rather announces their availability and provides a request form for printed versions. The document is about the publication of meeting materials and is not the meeting materials themselves. According to the classification rules, such a document is a Report Publication Announcement (RPA) because it announces the availability of corporate communications (meeting circular and notice) but does not contain substantive report content or financial data itself.
2024-08-27 English
Notification Letter and Request Form to H Shareholders - Notification of publication of Circular, Notice and Form of Proxy for the First Extraordinary General Meeting of 2024
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated 27 August 2024 from Pharmaron Beijing Co., Ltd. It informs shareholders about the publication of corporate communications related to the First Extraordinary General Meeting of 2024, including the circular, notice, and proxy form. The letter provides instructions on how shareholders can access these documents online or request printed versions. It explicitly states that the documents are available on the company's and HKEX's websites and that printed copies can be requested. The document does not contain the actual circular, notice, or proxy form content but serves as a notification of their publication and availability. The document length is 7038 characters, which is relatively short and consistent with a notification letter rather than a full report or meeting materials. According to the classification rules, such a document announcing the publication of reports or meeting materials without containing the full content itself should be classified as a Report Publication Announcement (RPA).
2024-08-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.